Study To Examine Effect Of CP-866,087 On Consumption And Craving Of Alcohol In Alcohol Dependent Subjects.

ClinicalTrials.gov ID: NCT00147576

Open the official record

This page only displays public information reproduced from the official ClinicalTrials.gov record NCT00147576. It adds no medical advice, opinions, or eligibility judgments. The official record remains the source of truth for eligibility criteria, enrollment, and contact information.

View official ClinicalTrials.gov record → Back to search

ClinicalTrials.gov public records Last synced Nov 13, 2026, 11:26 PM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Official title

Randomized, Placebo-Controlled Parallel Group Study Comparing Effect Of Three Doses Of CP-866,087 And Naltrexone On Acute Alcohol Consumption And Craving After Seven Days Of Treatment In Alcohol Dependent (DSM IV) Subjects Who Are Not Currently Seeking Treatment

Brief summary

Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.

Test the hypothesis that increasing doses of CP-866,087 will decrease the total number of drinks consumed during a 2 hour acute alcohol consumption assessment and to determine the safety and tolerability of multiple doses of CP-866,087 in alcohol dependent subjects compared to placebo.

Study identification

NCT ID: NCT00147576
Recruitment status: Completed
Study type: Interventional
Phase: Phase 2
Lead sponsor: Pfizer; Industry
Enrollment: 88 participants

Conditions and interventions

Conditions

Alcoholism

Interventions

CP-866,087 Drug

Drug

Eligibility (public fields only)

Age range: 21 Years to 65 Years
Sex: All
Healthy volunteers: Healthy volunteers not accepted

This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.

Study timeline

Start date: Dec 2003 (Type not available)
Primary completion: Not listed
Completion: Dec 2004 (Actual)
Last update posted: Oct 2, 2012

2003 – 2004

United States locations

U.S. sites: 11
U.S. states: 8
U.S. cities: 8

Facility	City	State	ZIP	Site status
Pfizer Investigational Site	Cerritos	California	90703	—
Pfizer Investigational Site	New Haven	Connecticut	06504	—
Pfizer Investigational Site	New Haven	Connecticut	06519	—
Pfizer Investigational Site	Washington D.C.	District of Columbia	20016	—
Pfizer Investigational Site	Melbourne	Florida	32901	—
Pfizer Investigational Site	Melbourne	Florida	32935	—
Pfizer Investigational Site	Lenexa	Kansas	66219	—
Pfizer Investigational Site	Providence	Rhode Island	02908	—
Pfizer Investigational Site	Charleston	South Carolina	29425	—
Pfizer Investigational Site	San Antonio	Texas	78229-3900	—
Pfizer Investigational Site	San Antonio	Texas	78229	—

Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.

About this trial record page

What this page shows: Public field values for ClinicalTrials.gov record NCT00147576, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
What this page does not do: No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
Where the data comes from: Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
Last refresh: Last update posted Oct 2, 2012 · Synced Nov 13, 2026